TWIST BIOSCIENCE CORP
NASDAQ: TWST (Twist Bioscience Corporation)
Last update: 8 hours ago41.07
-0.51 (-1.23%)
| Previous Close | 41.58 |
| Open | 41.29 |
| Volume | 1,539,364 |
| Avg. Volume (3M) | 1,438,626 |
| Market Cap | 2,516,508,928 |
| Price / Sales | 6.60 |
| Price / Book | 5.39 |
| 52 Weeks Range | |
| Earnings Date | 2 Feb 2026 |
| Profit Margin | -54.98% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -3.25 |
| Quarterly Revenue Growth (YOY) | 23.20% |
| Total Debt/Equity (MRQ) | 18.25% |
| Current Ratio (MRQ) | 4.51 |
| Operating Cash Flow (TTM) | -56.11 M |
| Levered Free Cash Flow (TTM) | -16.89 M |
| Return on Assets (TTM) | -15.04% |
| Return on Equity (TTM) | -38.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Twist Bioscience Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 1.98% |
| % Held by Institutions | 115.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| William Blair Investment Management, Llc | 30 Sep 2025 | 4,142,283 |
| Soleus Capital Management, L.P. | 30 Sep 2025 | 1,866,234 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 79.00 (Guggenheim, 92.36%) | Buy |
| Median | 42.00 (2.26%) | |
| Low | 39.00 (Barclays, -5.04%) | Buy |
| Average | 50.50 (22.96%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 34.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 26 Jan 2026 | 79.00 (92.35%) | Buy | 42.46 |
| TD Cowen | 08 Jan 2026 | 43.00 (4.70%) | Buy | 34.74 |
| Barclays | 15 Dec 2025 | 39.00 (-5.04%) | Buy | 31.07 |
| 17 Nov 2025 | 37.00 (-9.91%) | Buy | 26.46 | |
| Stephens & Co. | 04 Nov 2025 | 41.00 (-0.17%) | Buy | 30.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FINN PATRICK JOHN | - | 42.94 | -2,390 | -102,627 |
| Aggregate Net Quantity | -2,390 | |||
| Aggregate Net Value ($) | -102,627 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 42.94 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FINN PATRICK JOHN | Officer | 23 Jan 2026 | Sell (-) | 2,390 | 42.94 | 102,627 |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue |
| 18 Dec 2025 | Announcement | Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference |
| 04 Dec 2025 | Announcement | Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research |
| 14 Nov 2025 | Announcement | Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results |
| 04 Nov 2025 | Announcement | Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference |
| 03 Nov 2025 | Announcement | Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |